Windtree Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
WINT Nasdaq 8731 https://windtreetx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Windtree Therapeutics Inc

Windtree Therapeutics to Host Virtual R&D and Investor Day Focusing on the Cardiogenic Shock Market, Istaroxime, Company Strategy and Planned Near-Term Milestones - Jun 5th, 2023 12:00 pm
Windtree Therapeutics Reports First Quarter 2023 Financial Results and Provides Key Business Updates - May 15th, 2023 8:30 pm
10 Best Stocks to Buy for a Quick Return - May 11th, 2023 4:20 pm
Windtree Therapeutics Announces Publication from Its SEISMiC Pre Cardiogenic Shock Study Comparing Two Doses of Istaroxime - Apr 27th, 2023 12:00 pm
Windtree Therapeutics Announces Closing of $12.42 Million Underwritten Public Offering Including Full Exercise of Overallotment Option - Apr 24th, 2023 8:01 pm
Windtree Therapeutics Announces Pricing of Upsized $10.8 Million Underwritten Public Offering - Apr 20th, 2023 12:30 pm
Windtree Therapeutics Announces Issuance of New Dual Mechanism SERCA2a Activator Patent - Apr 17th, 2023 12:00 pm
Windtree Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Key Business Updates - Apr 3rd, 2023 11:35 am
Windtree Regains Compliance with Nasdaq - Mar 13th, 2023 12:00 pm
Windtree Finds Cardiogenic Shock Has High Cost of US Patient Care and Plans Innovation with the Unique Profile of Istaroxime - Mar 6th, 2023 1:00 pm
Windtree Announces Publication on its SERCA2a Activator Drug Candidate for Chronic and Acute Heart Failure - Feb 28th, 2023 1:00 pm
Windtree Announces Istaroxime Scientific Abstract Has Been Accepted at the 2023 Technology and Heart Failure Therapeutics Conference - Feb 27th, 2023 1:00 pm
Windtree Therapeutics Announces Issuance of New Istaroxime Patent from U.S. Patent and Trademark Office - Feb 24th, 2023 1:00 pm
Windtree Therapeutics Announces Reverse Stock Split - Feb 23rd, 2023 5:00 pm
Windtree Therapeutics to Raise $1.0 Million From the Exercise of Previously Issued Warrants - Jan 20th, 2023 1:37 pm
Nasdaq Grants Windtree Therapeutics 180-day Extension to Regain Compliance - Dec 5th, 2022 12:30 pm
Windtree Therapeutics, Inc. (WINT) Upgraded to Buy: Here's Why - Nov 18th, 2022 5:00 pm
Windtree Therapeutics Reports Third Quarter 2022 Financial Results and Provides Key Business Updates - Nov 14th, 2022 12:30 pm
Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a New Istaroxime Patent - Oct 25th, 2022 12:00 pm
Multiple insiders bought Windtree Therapeutics, Inc. (NASDAQ:WINT) stock earlier this year, a positive sign for shareholders - Oct 6th, 2022 10:50 am